Selected work
Outcomes over slide decks. Products that launched, organisations that changed.
A selection of recent and representative work. Most are described without naming the client — confidentiality is a baseline expectation in this work, not a special arrangement. Insiders will recognise some of them. We don't disclose clients on request.
AI Diagnostics · 2025–26
German market entry for an international AI dermatology engine.
International AI diagnostics company active across European pharmacy and telehealth markets. Market entry plan, partner negotiations with telemedicine platforms and insurers, regulatory positioning under MDR and the EU AI Act, and pricing models for multiple partner constellations.
- AI Strategy
- Market Access
- Partner Strategy
Medtech · 2025
Reimbursement strategy for an AI cardiac monitoring platform.
Global cardiac medical device manufacturer. Direct discussions with all major Krankenkassen on coverage criteria, contract models, and integration options. Evaluation of §140a, DiGA, and Integrated Care pathways. Clinical and health-economic evidence framework prepared for payers.
- Market Access
- Reimbursement
- Evidence Strategy
Hospital AI Scale-up · 2023–24
Interim CPO for an AI-native hospital management platform.
Stepped in after the previous CPO's departure with no break in delivery. AI features brought live in clinical operations: bed planning, clinical process optimisation, capacity management. End-to-end ownership of product strategy, sprint framework, and an 8-person engineering team.
- Interim Leadership
- AI in Production
Healthcare IT · 2024–26
Next-generation practice management platform — Discovery to Interim Product Leadership.
Two consecutive mandates. Discovery delivered platform requirements, target architecture, and a phased roadmap with full TI integration (ePA, KIM, e-prescription) — triggering the board's build decision. Interim leadership: 10-person engineering team, agentic AI architecture in production.
- Discovery
- Interim Leadership
- Agentic AI
Health Insurer (PKV) · 2024
Digital member engagement platform — concept and MVP definition.
Leading German private health insurer. Project leadership and concept ownership for an app-based bonus platform. Product concept, MVP scope, and incentive model designed to couple nudges directly to health outcomes — not activity metrics.
- Discovery
- Product Strategy
Health Insurer (PKV) · 2023
Hybrid prevention programme portfolio.
Discovery for three prevention programmes — rare diseases, cardiovascular health, chronic pain — designed as a coherent new product portfolio. Programmes deliberately structured as evidence-ready pilots: built to generate usable outcome data, not just to run.
- Portfolio Strategy
- Discovery
- Evidence Design
Digital Health NGO · 2022–23
Gestational diabetes DTx — venture build to DiGA-ready prototype.
Foundation-funded digital health non-profit. Venture build for a gestational diabetes app with daily coaching and glucose tracking. Value proposition coupled to German reimbursement pathways from day one — not retrofitted.
- Venture Building
- Discovery
International Market Entry · 2023
ADHS screening tool — German market entry strategy.
Singapore-based behavioural health and DTx company. Sequencing the market entry across providers, payers, and patients. Localisation, GKV alignment, and provider engagement strategy delivered.
- Market Access
- Go-to-Market
- Provider Strategy
International Market Entry · 2022
IAPT-inspired CBT platform — payer engagement and provider playbook.
Singapore-based digital mental health company. Payer engagement strategy plus a provider onboarding playbook that scales prescription and patient activation in a market where provider buy-in is a precondition for payer conversations.
- Payer Strategy
- Provider Activation
Pharma · 2022
Innovation operating model for global digital health partnerships.
Global medical device and diagnostics company. Strategy mandate to structure and operationally manage external innovation partnerships. Cooperation playbook adopted as the operating model for external innovation work.
- Innovation Strategy
- Operating Model
Life Sciences · 2021
Drug discovery research platform — business case and spinout decision.
Global life sciences company. Investment modelling to quantify the platform opportunity and inform the spinout decision. Stakeholder alignment across regions, functions, and hierarchies. Platform was subsequently spun out as an independent venture.
- Venture Building
- Investment Strategy
Pharma · 2019
Patient engagement programme — chronic pain.
Global pharmaceutical company. Programme design oriented to adherence and treatment outcomes as primary metrics. Coordination across an unusually complex stakeholder landscape spanning public health institutions, patient organisations, and pharma teams.
- Patient Engagement
- Programme Design
Digital Health NGO · 2019
Health record platform — discovery and business development.
Foundation-funded NGO. Discovery and BD to evolve an existing health record platform into new product directions. Stakeholder coordination across C-level, internal product and engineering teams, and external research partners.
- Discovery
- Business Development
Founder venture
2014–18
ONELIFE Health — built and scaled to reimbursement, US and Middle East market entries.
A certified digital health platform for female health and patient engagement. Reimbursement in Germany through cooperations with Krankenkassen. International market entries in the United States and the Middle East with adapted regulatory and reimbursement models. International team up to 20 FTE. Founder responsibility across funding rounds, investor relations, board work, and strategic partnerships.
The reason North Star Labs exists. Everything we advise on, we've done ourselves first.
Portfolio & clients
Companies I've worked with over the years.
In different capacities — as a founder, advisor, product lead, or venture partner.
Experts & partners
Tell us what you're building.
Whether you need a strategy, a product leader, a reimbursement path, or all three — the first conversation costs nothing and usually clarifies more than a formal brief.